MGMT
MimiVax to Begin Phase II Study of Immunotherapy Vaccine in Glioblastoma
The study will explore molecular predictors of response to MiMiVax's SurVaxM, including MGMT methylation status, IDH1 mutation, and survivin-specific responses.
Denovo Begins Phase III Glioblastoma Trial of Enzastaurin
The firm is evaluating enzastaurin plus chemo and radiation in glioblastoma patients with a biomarker, dubbed de novo genomic marker 1.
Kazia Therapeutics, Kintara Therapeutics Begin Trials in Glioblastoma Platform Study
The companies' treatments, paxalisib and VAL-083, are being studied in the GBM AGILE trial sponsored by the Global Coalition for Adaptive Research.
Bristol Myers Unblinds Trial After Opdivo, Chemoradiation Fail to Extend Survival in Glioblastoma
A data monitoring committee said that BMS's immunotherapy plus standard of care would not improve overall survival in MGMT-methylated brain cancer patients.
Kazia Therapeutics' Paxalisib to be Evaluated in Glioblastoma Study
The multi-cohort brain cancer study will include Kazia's investigational drug in a new arm, which will start enrolling patients in early 2021.